Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of diabetic nephropathy.

Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of macular degeneration.

Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.

Abstract: Novel pyridines, pyrimidines, pyrazines, pyridazines and triazines, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.

Abstract: This invention relates to derivatives of furan and thiophene, their composition, process of making and method of use as endothelin receptor antagonists.

Abstract: Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37.degree. C. and is highly immunogenic, for example when the vaccine is administered to infants. The compositions typically comprise HBsAg adsorbed to aluminium phosphate and other antigens, especially those suitable for use in a paediatric vaccine, adsorbed to aluminium phosphate or aluminium hydroxide. Methods for preparing the vaccines and the use of aluminium phosphate to stabilise HBsAg in a multivalent vaccine formulation are also described.

Abstract: For storage of syringes, a support rack comprising a plurality of elongate fingers (2) connected together at one end by a spine member (1) is used. The fingers (2) define parallel support channels (5) open at one end, and the syringes are stored in the channels (5) with their lips or wings (4) resting on the elongate fingers (2). Also disclosed are support cradles, storage boxes, and lifting devices for handling the loaded racks. The support rack is better adapted than existing systems for cooperation with automated machinery since it can receive syringes into the channels by a horizontal translation movement, readily provided by a simple pushing device.

Abstract: Novel herpes viral protease crystalline structures are identified which have an active site formed by the three amino acids Ser, His and His. Also disclosed are methods of identifying inhibitors of these proteases and/or active sites.

Abstract: This invention relates to compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation and bone resorption, pharmaceutical compositions for effecting such activity, and a method for using these compounds.

Abstract: Compounds of formula (I) ##STR1## wherein A.sub.1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R.sup.3 or R.sup.4 ; X.sup.1 --X.sup.2 is CHR.sup.1 --CH, CR.sup.1 .dbd.CH, NR.sup.1 --CH, S(O).sub.u --CH or O--CH; X.sup.3 is CR.sup.5 R.sup.5 ', NR.sup.5, S(O).sub.u or O; R.sup.2 is --OR', --NR'R", --NR'SO.sub.2 R'", --NR'OR', --OCR'.sub.2 C(O)OR', --OCR'.sub.2 OC(O)--R', --OCR'.sub.2 C(O)NR'.sub.2, CF.sub.3 or --COCR'.sub.2 R.sup.2 '; R.sup.3, R.sup.4 and R.sup.7 are independently H, halo, --OR.sup.12, --SR.sup.12, --CN, --NR'R.sup.12, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r --, --CO.sub.2 R', --CONR'.sub.2, R.sup.14 --C.sub.0-6 alky-, R.sup.14 --C.sub.1-6 oxoalkyl-, R.sup.14 --C.sub.2-6 alkenyl-, R.sup.14 --C.sub.2-6 alkynyl-, R.sup.14 --C.sub.0-6 alkyloxy-, R.sup.14 --C.sub.0-6 alkylamino- or R.sup.14 --C.sub.0-6 alkyl--S(O).sub.r --; R.sup.6 is W--(CR'.sub.2).sub.q --Z--(CR'R.sup.10)--U--(CR'.sub.2).sub.s --V-- or W'--(CR'.sub.2).sub.

Abstract: The novel compounds of Formula (I) have been found to be useful cytokine suppressive agents and therefore useful in the treatment and prophylaxis of disease states mediated thereby.

Abstract: Mupirocin or a salt or ester thereof may be used to treat recurrent sinusitis and recurrent otitis, in particular with novel spray or cream formulations adapted for administration to the nasopharynx.

Abstract: This invention relates to the novel pyrazole compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of inhibiting cytokines by a compound of Formula (I) and the treatment of cytokine mediated diseases, in mammals, by administration of said compound.

Abstract: Disclosed herein is a compound of the formula ##STR1## known as 2-[N-(N-benzyloxycarbonyl-L-leucinyl)]-2'-[N'-[4-(N,N-dimethylaminomethyl) benzyloxy]carbonyl-L-leucinyl]carbohydrazide; and pharmaceutically acceptable salts, hydrates and solvates thereof.

Abstract: A compound of formula (I) or a salt thereof: ##STR1## wherein: P.sup.1 is pyridyl;P.sup.2 is phenyl;A is a bond or a chain of 1 to 5 atoms optionally substituted by C.sub.1-6 alkyl;R.sup.1 and R.sup.2 groups are each independently hydrogen, C.sub.1-6 alkyl optionally substituted by NR.sup.12 R.sup.13, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, cyano, halogen, CF.sub.3, NR.sup.12 R.sup.13, CHO, OCF.sub.3, COR.sup.14, CH.sub.2 OR.sup.14 or OR.sup.14 where R.sup.12, R.sup.13 and R.sup.14 are independently hydrogen or C.sub.1-6 alkyl;n and m are independently 0, 1 or 2;R.sup.3 is hydrogen or C.sub.1-6 alkyl;R.sup.4 is a group of formula (i): ##STR2## in which: R.sup.6 and R.sup.7 are independently hydrogen, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, C.sub.1-6 alkylthio, C.sub.1-6 alkoxy or halogen.

Abstract: Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.

Abstract: Novel indane and indene derivatives are described which are endothelin receptor antagonists.

Abstract: A compound of formula (I) or a salt thereof, or a solvate thereof, wherein either (i) Ra represents a group R.sub.5 which is hydrogen, alkyl or optionally substituted aryl and R.sub.5 represents a moiety of formula (a); wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substituted or unsubstituted or X represents a group NR.sub.s R.sub.t wherein R.sub.s and R.sub.t each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or R.sub.s and R.sub.t together may form a heterocyclic group; R.sub.1 represents an alkyl or a substituted or unsubstituted aryl group; and R.sub.2, R.sub.3 and R.sub.4 each independently represent hydrogen, alkyl, aryl or substituted aryl or (ii) R.sub.a represents a moiety of the above defined formula (a) and R.sub.b represents the above defined R.sub.5 ; R.

Abstract: Substrate beads for combinatorial synthesis are selected individually from a mixture by suspending the mixture in an electrically conductive liquid, in a bead selection vessel, causing the liquid to flow at a controlled rate through an aperture in the side wall of a pipette extending through the vessel, and detecting the passage of a bead through the aperture by monitoring an electrical resistance across the aperture. In an alternative embodiment, beads are passed through a tube into a collection passage in which a continuous laminar flow takes place. Detection takes place at the tip of the tube, and, in response to the detection of a bead, the flow through the collection passage is diverted to cause the bead to be deposited. In both cases, the selected bead is deposited into a well of a plate having rows and columns of wells in a rectangular array, while a vacuum is drawn through a filter in the bottom of the well.